Ipsen doing interviews for new Oncology division and I've been called to do one. Not sure about it. It appears that Novartis' Sandostatin LAR will be competition. What is this market Like? How is Novartis preparing you for this change? You guys think it will make an impact? I definitely don't want to take something that is going to completely suck.
New Competition with Ipsen
Aucun commentaire:
Enregistrer un commentaire